Earnings summaries and quarterly performance for Dermata Therapeutics.
Research analysts covering Dermata Therapeutics.
Recent press releases and 8-K filings for DRMA.
Dermata Therapeutics Announces Up to $12.4 Million Private Placement
DRMA
New Projects/Investments
Product Launch
M&A
- Dermata Therapeutics has entered into definitive agreements for a private placement expected to generate approximately $4.1 million in gross proceeds upfront, with potential additional gross proceeds of approximately $8.3 million upon the full exercise of accompanying warrants.
- The offering involves the issuance of 2,022,062 shares of common stock (or pre-funded warrants) and accompanying series C and D warrants, priced at $2.04 per share.
- Company insiders, including the Chief Executive Officer and Chief Financial Officer, are participating in the private placement, purchasing an aggregate of approximately $1.5 million in shares and warrants.
- The net proceeds, estimated at approximately $3.7 million, are intended for general corporate purposes, including consumer research studies, pre-launch and launch activities for the company’s new OTC acne kit, and investing in or acquiring synergistic companies.
- Additionally, certain outstanding warrants issued on January 23, 2025, with an exercise price of $12.70 per share, will be amended to a reduced exercise price of $2.04 per share.
Dec 29, 2025, 9:05 PM
Dermata Therapeutics Announces Private Placement
DRMA
New Projects/Investments
- Dermata Therapeutics entered into definitive agreements for a private placement expected to generate $4.1 million upfront and up to an additional $8.3 million if warrants are fully exercised, totaling up to $12.4 million.
- The placement involves the issuance of 2,022,062 shares (or pre-funded warrants) and accompanying Series C and D warrants at $2.04 per share.
- Company insiders, including the CEO and CFO, are participating in the offering on the same terms as other investors.
- The financing aims to bolster Dermata's position as a late-stage medical dermatology company developing topical candidates using its Spongilla technology.
- Following the announcement, the company's stock experienced a premarket jump of roughly 46.6% to $2.99.
Dec 24, 2025, 1:15 PM
Dermata Therapeutics Presents Positive Phase 3 Clinical Data for XYNGARI™
DRMA
Product Launch
New Projects/Investments
- Dermata Therapeutics, Inc. (DRMA) presented positive clinical data from its XYNGARI™ (DMT310) Phase 3 Spongilla Treatment of Acne (STAR-1) clinical trial at the European Academy of Dermatology and Venereology Congress 2025.
- The trial demonstrated statistically significant differences in Investigator Global Assessment (IGA) treatment success for XYNGARI™ compared to placebo at weeks 4, 8, and 12. At week 12, 29.4% of XYNGARI™ patients achieved IGA treatment success (2-point reduction and score of 0 or 1) versus 15.2% for placebo (p < 0.001).
- XYNGARI™ also showed statistically significant improvements in mean and percent change from baseline for both inflammatory and non-inflammatory lesion counts at weeks 4, 8, and 12 compared to placebo. For example, at week 12, the percent change from baseline in inflammatory lesion count was 59.1% for XYNGARI™ versus 45.3% for placebo (p < 0.001).
Sep 17, 2025, 10:05 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more